Endurance Wealth Management Inc. decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 24,010 shares of the biopharmaceutical company’s stock after selling 2,150 shares during the quarter. Endurance Wealth Management Inc.’s holdings in Gilead Sciences were worth $1,720,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently added to or reduced their stakes in the stock. Keel Point LLC raised its holdings in Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 12 shares in the last quarter. Paradigm Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC raised its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 41 shares during the period. Auxier Asset Management raised its holdings in shares of Gilead Sciences by 1.4% in the 2nd quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock worth $479,000 after purchasing an additional 96 shares during the period. Finally, Edmonds Duncan Registered Investment Advisors LLC raised its holdings in shares of Gilead Sciences by 1.6% in the 2nd quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 77.96% of the company’s stock.
In other news, CFO Robin L. Washington sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares in the company, valued at $1,907,282.19. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director John Francis Cogan sold 5,833 shares of the stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $80.93, for a total transaction of $472,064.69. The disclosure for this sale can be found here. In the last quarter, insiders have sold 430,268 shares of company stock worth $34,074,395. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter last year, the firm earned $2.70 earnings per share. The business’s revenue for the quarter was down 18.7% on a year-over-year basis. equities research analysts expect that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is currently 27.05%.
A number of equities research analysts recently commented on GILD shares. Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. Credit Suisse Group restated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Finally, Wells Fargo raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $79.02 to $96.00 in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $88.61.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/03/17/endurance-wealth-management-inc-sells-2150-shares-of-gilead-sciences-inc-gild/1903904.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.